Sign in

NCT04197336Completed

Bariatric Embolization of Arteries With Imaging Visible Embolics (BEATLES)

Bariatric Embolization of Arteries With Imaging Visible Embolics

Source: ClinicalTrials.gov · Last updated 17 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The BEATLES study is an investigator-initiated, prospective, double-blinded, randomized, sham-controlled study that will assess the impact of bariatric embolization on the systemic levels of obesity-related hormones and, as a consequence, on weight loss. The goal of this study is to help treat obesity combining a lifestyle program and a minimally invasive, angiographic (i.e., through blood vessels) approach.

Status (registry)
Completed
Study type
Interventional
Enrollment
10 (actual)
First submitted
11 Dec 2019
Start date
10 Jan 2020
Primary completion date
14 Dec 2023
Lead sponsor
Johns Hopkins University
Diseases
Obesity
NCT number
NCT04197336

What you commit to

  • Study type: Interventional
  • Participants enrolled: 10
  • From 10 Jan 2020 to the primary completion date, 14 Dec 2023
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients who are currently taking either Insulin or sulfonylurea (medication changes are allowed)
  • Prior history of gastric, pancreatic, hepatic, and/or splenic surgery
  • Prior radiation therapy to the upper abdomen
  • Prior embolization to the stomach, spleen, or liver
  • Weight loss (intentional or unintentional) of more than or equal to 5% of body weight in the 6 months prior to randomization
  • Use of anti-obesity medications in the 12 months prior to screening
  • Inability to have an MRI scan (i.e., metal implants or claustrophobia)
  • As determined by clinical judgment based on Clinical Interview, psychological/behavioral measures, medical records, previous mental health records/other collateral information (as available) and consistent with diagnostic and statistical manual of mental disorders (DSM) -5 criteria:
  • Limited capacity to make informed decision about procedure and inability to verbalize an understanding of the surgical procedure, risks and benefits.

Other illness

  • Known portal venous hypertension
  • Active peptic ulcer disease
  • Significant risk factors for peptic ulcer disease, including daily NSAID use
  • Active H. Pylori infection
  • Renal insufficiency, as evidenced by an estimated glomerular filtration rate of \<60 milliliter(mL)/min
  • Major comorbidity, such as active cancer, significant cardiovascular disease, or peripheral arterial disease
  • GI bleeding or bleeding diathesis within 5 years
  • History of gastric motility disorders or an abnormal nuclear gastric motility examination (to be performed in diabetic subjects only)
  • American Society of Anesthesiologists Class 4 or 5 (very high risk surgical candidates: class 4=incapacitating disease that is a constant threat to life) at the time of screening for enrollment into the study - this exclusion criterion exists, because of the possibility that surgical intervention will be needed if the study intervention subsequently leads to severe adverse effects
  • Inflammatory bowel disease
  • Autoimmune disease or HIV+
  • History of allergy to iodinated contrast media
  • Failure to comply with pre-procedure weight management "run-in", or other pre-procedural visits (specifically, participants must complete 80% of weight management and Lose It! Food tracking, and 100% of one-time visits, i.e. MRI, computed tomography angiography (CTA), endoscopy)
  • Active or new-onset endocrine disorders (stable disease acceptable)
  • Other unforeseen conditions that may make patients unsuitable for the procedure (study team discretion)
  • Diagnosis of severe mental illness (i.e., chronic psychotic spectrum disorders, clinically significant mood disorders) AND/OR one or more of the following:
  • Evidence of active relapse or active impairing symptoms (e.g., suicidal ideation, audio or visual hallucinations, paranoia, thought disturbance, severe impairment)
  • Failure to provide comprehensive aftercare plan that includes emergency plan for addressing future mental health relapse
  • History of treatment refractory mental illness/recurrent relapse (multiple suicide attempts or inpatient psychiatric hospitalizations in the past 5 years)
  • Within past 3 years: Inpatient psychiatric hospitalization
  • Cognitive impairment, if judged to have
  • History of Anorexia or History of/Active Bulimia: If determined to be of low enough severity not to be a clear contraindication, minimum of 5 years abstinence from bulimia, current moderate to severe binge eating or night eating syndrome
  • Active or History of Substance Abuse with less than 5 years of abstinence
  • Current use of anti-tricyclic anti-depressants or steroids, psychiatric medications associated with weight gain.

Lab values

  • hemoglobin A1c greater than 8%

Other

  • Cirrhosis
  • Large hiatal hernia, defined as \>5 cm in size
  • Known aortic pathology, such as aneurysm or dissection
  • Pregnancy
  • Pre-existing chronic abdominal pain
  • Positive stool occult blood study
  • A weight loss greater than 6lb during the weight management run- in
  • Endoscopic findings that would preclude bariatric embolization (at the discretion of the study team)
  • Applicability of any contraindication regarding patient's vasculature as per Instruction for Use
  • Smokers/vape users/tobacco use
  • Evidence of minimal supports or limited adherence to ongoing mental health care
  • Within past 5 years: Suicide attempt
  • Declining to provide mental health records, a letter of support from mental health professionals, or consent for verbal consultation with mental health professionals when determined to be essential to evaluation.
  • Inability to demonstrate an understanding of the permanency of lifestyle change required

Who the study is looking for

  • Male or female, aged ≥21 and ≤70 years
  • Willing, able, and mentally competent to provide written informed consent
  • Obese patients with a BMI ≥35 kg/m2
  • Weight ≤400 lb
  • Vascular anatomy (including celiac, hepatic, and gastric arteries) that in the opinion of the interventional radiologist is amendable to bariatric embolization, as assessed via 3D CT angiography
  • Suitable for protocol therapy, as determined by the interventional radiology investigator
  • Adequate hematologic (neutrophils\>1.5x109/L, platelets\>70x109/L, international normalized ratio (INR\<1.5), hepatic (bilirubin≤2.0mg/dL, albumin≥2.5g/L), and renal (estimated glomerular filtration rate (GFR)\>60milliliter mL/min. 1.73m2) function
  • For females of reproductive potential: agreement to use of highly effective contraception
  • for duration of study participation
  • Patients who have failed conservative weight loss therapies such as supervised low calorie diets combined with behavior therapy and exercise
  • Live or work within 65 miles of the enrolling institution in case a catastrophic post embolization event occurs

Age in the registry: 21 years to 70 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Johns Hopkins University
Coordinator of this site? Confirm its status
BaltimoreUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.